Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Does the World Continue to Struggle with Preventable Patient Harm?

Patient safety is something every healthcare organization wants to improve upon, especially with the shift to value-based care. However, most are missing the mark with preventable patient harm and truly being patient-centric. Discussing the topic today, B2B Today host Daniel Litwin spoke with Dr. Donna Prosser, Chief Clinical Officer of the Patient Safety Movement Foundation, a nonprofit…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Patient safety is something every healthcare organization wants to improve upon, especially with the shift to value-based care. However, most are missing the mark with preventable patient harm and truly being patient-centric. Discussing the topic today, B2B Today host Daniel Litwin spoke with Dr. Donna Prosser, Chief Clinical Officer of the Patient Safety Movement Foundation, a nonprofit that’s goal to reach zero preventable patient harm and deaths. The company will host the #UniteForSafeCare event on World Patient Day on September 17.

“There had been success in improving patient safety, but that fell apart during COVID because there was a hyper-focus. It comes down to the lack of a high-reliability foundation,” Dr. Prosser noted.

“Hospitals are businesses and concerned about public image and marketability. That sustains a culture of silence where no one talks about the issues.” – Dr. Donna Prosser

Dr. Prosser argued that while organizations say they are patient-focused, the processes and structure of healthcare is clinician-focused. That could be why some clinicians seem to make numerous errors undetected, as seen in the upcoming TV show Dr. Death, which centers on a real neurosurgeon’s medical incompetence.

“This is at the far end of the spectrum, but other situations happen regularly because of the way the system is set up. Transparency, openness, and trust aren’t there. People saw this behavior and didn’t feel comfortable voicing it or hit a wall if they did,” Dr. Prosser explained.

This “culture of silence” is what perpetuates preventable patient harm. That’s reflected in research. One survey found that 6% of patients were affected, while another from the World Health Organization (WHO) found that four in 10 patients suffered some harm.

So, what’s the answer to address preventable harm? Dr. Prosser said, “No one can do it alone. All stakeholders have to be at the table. We have to band together, shine a light on it, address it, and create those highly reliable systems. It will require culture change.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512